NA
XFOR icon

Neuburgh Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

Neuburgh Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$20K Buy
+54
New +$21.4K ﹤0.01% 888

Other funds holding XFOR

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Neuburgh Advisers's XFOR Position: Q3 2019 in Review

Neuburgh Advisers opened a new position in X4 Pharmaceuticals (XFOR) in Q3 2019: 54 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #888 among its holdings.

49 funds tracked by Wall St. Rank hold XFOR as of Q3 2019.

  • Neuburgh Advisers held 54 shares of X4 Pharmaceuticals worth $20K as of Q3 2019.
  • X4 Pharmaceuticals was a new Neuburgh Advisers position in Q3 2019.
  • X4 Pharmaceuticals made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #888 holding.
  • 49 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.